Evidence map›Paper›PMID 28427211›Full record

ArticleOncotarget2017

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.

Grzegorz J Korpanty, Lawson Eng, Xin Qiu, Olusola Olusesan Faluyi, Daniel J Renouf, Dangxiao Cheng, Devalben Patel, Zhuo Chen, Brandon C Tse, Jennifer J Knox and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Frontiers in immunology · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Grzegorz J KorpantyPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Lawson EngPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Xin QiuPrincess Margaret Cancer Centre, Department of Biostatistics, University Health Network, Toronto, ON, Canada.
Olusola Olusesan FaluyiPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Daniel J RenoufDepartment of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC, Canada.
Dangxiao ChengPrincess Margaret Cancer Centre, Department of Medical Biophysics, University Health Network, Toronto, ON, Canada.
Devalben PatelPrincess Margaret Cancer Centre, Department of Medical Biophysics, University Health Network, Toronto, ON, Canada.
Zhuo ChenPrincess Margaret Cancer Centre, Department of Medical Biophysics, University Health Network, Toronto, ON, Canada.
Brandon C TsePrincess Margaret Cancer Centre, Department of Medical Biophysics, University Health Network, Toronto, ON, Canada.
Jennifer J KnoxPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Lorin DodbibaPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Jennifer TeichmanPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Abul Kalam AzadPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Rebecca WongPrincess Margaret Cancer Centre, Radiation Medicine Program, University Health Network, Toronto, ON, Canada.
Gail DarlingDepartment of Surgery, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
David ReismanDepartment of Medicine in the College of Medicine, Division of Hematology and Oncology, University of Florida, Gainesville, FL, USA.
Sinead CuffePrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, Department of Medicine, University Health Network, Toronto, ON, Canada.
Wei XuPrincess Margaret Cancer Centre, Department of Biostatistics, University Health Network, Toronto, ON, Canada.
Princess Margaret Cancer Centre · CAUniversity Health Network · CABC Cancer Agency · CAPublic Health Ontario · CAToronto General Hospital · CAUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBrahma (BRM) is a critical catalytic subunit of the SWI/SNF chromatin remodeling complex; expression of BRM is commonly lost in various cancer types. BRM promoter polymorphisms (BRM-741; BRM-1321) are associated with loss of BRM expression, and with cancer risk/survival. We evaluated these two polymorphisms in the overall survival (OS) of esophageal adenocarcinoma (EAC) patients.

resultsOf 270 patients, 37% were stage IV. Minor allele frequencies were 47-49%; 15% were double-homozygotes. When compared to the wild-type genotype, the homozygous variant of BRM-741 carried an adjusted OS hazard ratio (aHR) of 1.64 (95% CI:1.1-2.4); for BRM-1321, the aHR was 2.09 (95% CI:1.4-3.0). Compared to the double wild-type, carrying homozygous variants of both promoter polymorphisms (double-homozygote) yielded an aHR of 2.21 (95% CI:1.4-3.6). Directions/magnitudes of associations were similar in subsets by age, gender, smoking status, use of platinum agents, and disease stage, and for progression-free survival. MATERIALS AND

methodsIn a cohort of EAC patients of all stages (84% male; median age of 64 years), two BRM polymorphisms were genotyped. Cox proportional hazards models, adjusted for known prognostic variables, estimated the association of polymorphisms with OS.

conclusionsBRM polymorphisms were associated with OS in EAC in this study. Validation studies are warranted.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseasePolymorphism, GeneticPromoter Regions, GeneticAdenocarcinomaAdultAgedAged, 80 and overAllelesCombined Modality TherapyEsophageal NeoplasmsFemaleGene FrequencyGenotypeHumansMaleSMARCA2 protein, humanTranscription Factorsbrahmacancer prognosischromatin remodelingesophageal cancerpolymorphism

Identifiers

PMID28427211
PMCPMC5438633
OpenAlexW2593659568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.